NetworkNewsBreaks – NRx Pharmaceuticals, Inc. (N
Post# of 67

NRx Pharmaceuticals (NASDAQ: NRXP) announced that its wholly owned subsidiary, HOPE Therapeutics(TM), has signed a term sheet with Universal Capital, LLC for $7.8 million in acquisition funding to support the rollout of its national interventional psychiatry clinic network. Combined with previously announced investments, HOPE now has $10.3 million in capital to execute initial acquisitions of Dura Medical, Kadima, and NeuroSpa. These clinics offer neuroplastic treatments such as ketamine and transcranial magnetic stimulation to treat severe depression and PTSD, with current contracts in place to serve veterans through the VA. Universal Capital expects to participate in future funding rounds as HOPE expands its platform nationwide.
For more information, please visit https://www.nrxpharma.com/
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer

